Hologic Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 11/20/2025)
| Balance Sheet | Total Assets | 9,014,900,000.00 | ROE | – |
| Balance Sheet | Total Equity | 5,047,900,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -137,000,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | 920,100,000.00 | – | – |
| Cashflow | Operating Cash Flow | 1,057,100,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | 2.49 | Div. Yield | – |
| Income | Net Income | 565,700,000.00 | P/E | – |
| Income | Shares Outstanding | 227,573,000.00 | P/B | – |
| Income | Total Revenue | 4,100,500,000.00 | P/S | – |
Ratios calculated on: –
Company Description
Hologic, Inc. is a developer, manufacturer and supplier of diagnostics products, medical imaging systems and surgical products to serving the healthcare needs of women. The Company operates in four segments: Breast Health, Diagnostics, GYN Surgical and Skeletal Health. The Company sells and services its products through a combination of direct sales and service forces and a network of independent distributors and sales representatives. On August 1, 2012, the Company acquired Gen-Probe Incorporated (Gen-Probe). Gen-Probe is engaged in molecular diagnostics products and services, which are used to diagnose human diseases, screen donated human blood and test transplant compatibility. In March 2013, it announced that it has completed its sale of the LIFECODES business unit to Immucor, Inc.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.hologic.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more